Nektar TherapeuticsNKTRNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
12.58%
↑ 107% above average
Average (39q)
-169.40%
Historical baseline
Range
High:1222.45%
Low:-7108.11%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 12.58% |
| Q2 2025 | 18.65% |
| Q1 2025 | -410.39% |
| Q4 2024 | 141.78% |
| Q3 2024 | 31.00% |
| Q2 2024 | -40.50% |
| Q1 2024 | -5.72% |
| Q4 2023 | 25.31% |
| Q3 2023 | 11.33% |
| Q2 2023 | 62.44% |
| Q1 2023 | -229.45% |
| Q4 2022 | -9.12% |
| Q3 2022 | 19.92% |
| Q2 2022 | 59.34% |
| Q1 2022 | -1.93% |
| Q4 2021 | 0.60% |
| Q3 2021 | -3.08% |
| Q2 2021 | -0.74% |
| Q1 2021 | 1.20% |
| Q4 2020 | -7.44% |
| Q3 2020 | -32.61% |
| Q2 2020 | 12.14% |
| Q1 2020 | 19.33% |
| Q4 2019 | -11.04% |
| Q3 2019 | 11.02% |
| Q2 2019 | 8.05% |
| Q1 2019 | -20.33% |
| Q4 2018 | -1.68% |
| Q3 2018 | -110.13% |
| Q2 2018 | 1222.45% |
| Q1 2018 | -260.90% |
| Q4 2017 | -134.59% |
| Q3 2017 | 237.17% |
| Q2 2017 | 6.95% |
| Q1 2017 | -69.35% |
| Q4 2016 | 2.30% |
| Q3 2016 | 14.15% |
| Q2 2016 | -304.10% |
| Q1 2016 | 67.70% |
| Q4 2015 | -7108.11% |